AstraZeneca Sinks on Crestor Trial

BOSTON ( TheStreet) -- AstraZeneca's ( AZN) hopes of differentiating its anti-cholesterol drug from the top-selling Lipitor have been dashed.

AstraZeneca said its Crestor anti-cholesterol medicine failed to beat Pfizer's ( PFE) Lipitor in a head-to-head clinical trial, dubbed Saturn. AstraZeneca had hoped the trial would differentiate Crestor and eat into Lipitor's $12 billion in sales.

While the Saturn trial showed Crestor had a "numerically greater" reduction in artery-clogging plaque in patients compared to Lipitor, the results were not statistically significant.

A secondary measure did show Crestor had a statistical significance over Lipitor, AstraZeneca said.

AstraZeneca shares trading in London were down nearly 3%.

-- Written by Robert Holmes in Boston.

>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet.

>To submit a news tip, send an email to: tips@thestreet.com.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

CEOs Are Dropping Like Flies

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting